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Abstract
Background—A lymphatically delivered nanoconjugate of cisplatin was evaluated in an orthotopic
mouse model of locoregionally metastatic breast cancer (LABC) to determine if it can overcome
some of the limitations of standard cisplatin therapy such as high systemic toxicity.
Methods—Human breast cancer cells (107 MDA-MB-468LN) were injected into the mammary fat
pad of female nu/nu mice. Once tumor volume reached 50 mm3; intravenous cisplatin or
subcutaneous hyaluronan-cisplatin [HA-cisplatin] nanoconjugate was given 1/week × 3 at 3.3 mg/
kg (platinum basis).
Results—Nanoconjugates co-localized with the tumors after subcutaneous peritumoral injection
and demonstrated improved efficacy to intravenous cisplatin. After one month, renal tubular
hemorrhage and edema were more prevalent in the intravenous formulation compared to
subcutaneous HA-cisplatin nanoconjugates.
Conclusions—This nanocarrier delivery platform focuses drug in the areas where tumor burden
is greatest, potentially reducing systemic toxicity, and has future applicability as a neoadjuvant or
adjuvant therapy for LABC.
SUMMARY
Locoregional delivery of cisplatin to the breast and axilla using a subcutaneously injected
hyaluronic acid nanoconjugate demonstrated improved efficacy and decreased toxicity
compared to intravenous cisplatin in a murine orthotopic model of locally advanced breast
cancer and may hold promise for future clinical studies.
Excluding skin cancers, breast cancer is the leading cause of cancer in women today and next
to lung cancer is the second most common cause of cancer deaths in women 1. Despite the
excellent short-term prognosis with current treatments, over 60% of women with localized
breast cancer eventually develop distant, late-stage disease 2.
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Neoadjuvant chemotherapy is considered standard of care for locally advanced breast cancer
(LABC), given to decrease tumor size allowing for subsequent breast conservation surgery,
radiation, and further adjuvant chemotherapy. The goal of neoadjuvant therapy is to not only
treat locoregional and systemic disease but to also inhibit further development of
micrometastases, angiogenesis and release of serum growth factors. The major problem
associated with these chemotherapeutics is toxicity, often leading to hospitalizations or other
treatments. Hassett et al. 4 compared outcomes within the first year of treatment among 3,526
newly diagnosed breast cancer patients 63 years or younger; 61% of chemotherapy patients
were hospitalized or were treated at hospital emergency rooms, compared with 42% of the
patients treated without chemotherapy.
Cisplatin (cis-diaminedichloroplatinum(II); (CDDP) attacks cancer cells by promoting DNA
binding and crosslinking. The most significant, dose-limiting toxicities of CDDP therapy are
neurotoxicity and nephrotoxicity, both of which are strongly influenced by peak plasma
concentration6. Additionally, most patients (as high as 75% to 100%) treated with CDDP show
some level of ototoxicity. This toxicity is cumulative and can be irreversible. Fractional or
metronomic dosing schedules that divide the same total dose of CDDP over several smaller
injections (e.g. daily), have been shown to significantly reduce nephrotoxicity and ototoxicity
9, 10 due to lower peak plasma concentration, but metronomic dosing requires more frequent
treatments, longer in-hospital stays, and leads to increased care costs thus far limiting its use
in practice. Overall toxicities associated with CDDP have led it to be considered in many cases
a second-line therapy in breast cancer and typically used in combination with other cytotoxic
drugs.
Currently no therapeutic drugs are designed for locoregional lymphatic treatment, and all
current chemotherapies for breast cancer are delivered systemically and have relatively poor
penetration into the lymphatics. From these data it can be concluded that there is a critical need
to develop better adjuvant and neoadjuvant therapies or delivery methods that decrease local
and systemic toxicity to the patient. Direct chemotherapy to the lymphatics using nanocarriers
may be the solution. Localized chemotherapy avoids systemic toxicity by restricting
chemotherapy agents to diseased tissue areas without subjecting other “unaffected” areas
(normal tissue) to harmful drug concentrations that damage these cells irrespectively. Local
chemotherapy is implemented in limb perfusions for limb-isolated melanomas and hepatic
artery pumps in some hepatic cancers 11, 12. Unfortunately, no such technique exists currently
for breast cancers. In this report, we describe using the unique drainage properties of the
lymphatic system, along with nanoparticle drug carriers that can be targeted to the lymphatics
of the breast, preventing systemic toxicity13.
MATERIALS AND METHODS
Nanoconjugate synthesis
Hyaluronan-cisplatin(HA-Pt) nanoconjugates were formed by stirring 10% weight/volume (w/
v) hyaluronan (HA,; 35 kDa; Lifecore Biomedical, Chaska, MN) and 4.5% w/v CDDP (Sigma
Aldrich, St. Louis, MO) in water, protected from light, for 4 days. The mixture was then filtered
(0.2-μm nylon membrane) and dialyzed against water (10 kDa cellulose tubing, Pierce,
Rockford, IL) for 48 hrs at 4°C, lyophilized, and CDDP conjugation was determined by atomic
absorption spectroscopy (Varian SpectAA GTA-110). Nanoconjugates typically contained
25% weight/weight covalently linked CDDP.
Cell toxicity studies in vitro
The lymphatically metastatic breast cancer cell line MDA-MB-468LN was maintained in
modified Eagle’s medium alpha supplemented with 10% fetal bovine plasma, 1% L-glutamine,
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and 0.4 mg/ml G418.13,16 Preceding proliferation studies, cells were trypsinized and seeded
into 96-well plates (5,000 cells/well). After 24 hrs, CDDP, HA-Pt (with or without silver
activation), or HA was added (n=12; 7 concentrations), and 72 hrs post-addition, resazurin blue
in 10 μl of phosphate-buffered saline was added to each well (final concentration of 5 mM).
After 4 hrs, well fluorescence was measured ( λex 560 nm, λem 590 nm) using a
fluorophotometer (SpectraMax Gemini; Molecular Devices, Sunnyvale, CA). IC50 was
determined as the midpoint between saline (positive) and cell-free (negative) controls for each
plate. For comparison, two other breast cancer cell lines (MDA MB-231 and MCF-7) were
tested in similar fashion with IC50 levels calculated.
Pathology studies
Healthy Sprague-Dawley rats (250–300 g, Charles River) were randomly divided into two
groups and administered CDDP intravenously via the tail vein or HA-Pt subcutaneously into
the mammary fat pad (1.0 or 3.3 mg/kg platinum basis, n=5/group). The animals were
euthanized after 4 weeks and the liver, bilateral kidneys, spleen, lungs, heart, right (ipsilateral)
and left (contralateral) axillary nodes, and brain were excised intact and stored in 80% alcoholic
formalin solution overnight for fixation before slide mounting. Mounting using haematoxylin
& eosin (H&E) staining were conducted by Veterinary Lab Resources (Kansas City, KS). The
pathological examination was performed by a blinded board-certified veterinarian pathologist
(University of Kansas Medical Center, Kansas City, KS). Animal procedures were approved
by the University of Kansas Institutional Animal Care and Use Committee.
In vivo tumor model and treatment
The MDA-MB-468LN breast cancer cells were trypsinized (0.25% w/v trypsin) and prepared
in 1×PBS solution at three different cell concentrations (105, 106, 107 cells/mL). Cells (100
μL) were injected under pentobarbital sedation into the mammary fat pad of female nu/nu mice
using a 27-ga needle through a 5-mm incision (20–25 g, Charles River). The incision was
closed with a sterilized staple and was removed a week after when the incision was healed.
The MDA-MB-468LN cell is transformed with a green fluorescent protein (GFP), so tumor
growth was monitored by fluorescent whole body imaging using a CSI Maestro imaging system
(Woburn, MA) and tumor size was measured twice a week with a digital caliper. Tumor volume
was calculated using equation: tumor volume (mm3) = 0.52×(width)2×length. Animals were
euthanized before the study’s end when their tumor size reached 2000 mm3 or the body score
index fell under 2. Tumors of 50 to 100 mm3 were observed after 3 weeks, and animals were
randomly divided into 4 different treatment groups. Treatments were administered in the third
and fourth weeks after tumor cells implantation.
RESULTS
In vitro characterization of nanoconjugates
Prior to in vivo studies, nanoconjugates were evaluated in vitro for their ability to inhibit breast
cancer cell growth. CDDP lends itself to complex formation with polycarboxylic polymers,
since one or more of the chlorides can be displaced allowing formation of a labile ester linkage
with the polymer 17. CDDP was highly conjugated to hyaluronan, with typical nanoconjugates
having 25% weight/weight platinum/complex (approximately 65% conjugation efficiency) and
a release half-life of 10 hours in saline. Cell toxicity was determined as the reduction in cell
proliferation over 72 hrs. HA-Pt nanoconjugates had similar cytotoxicity (IC50)in vitro to the
standard CDDPformulation in multiple breast cancer cell lines tested: MDA-MB-468LN, 3.9
and 3.6 μM (CDDP, HA-Pt);MDA-MB-231, 5.9 and 5.9 μM; and MCF-7, 5.7 and 5.2μM. HA
showed no toxicity at 10 mg/ml, the upper limit of testing (data not shown).
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In vivo efficacy analysis in xenografts
Control animals demonstrated a standard tumor growth curve at 106 cells/injection with tumor
volumes exceeding 1000 mm3 at 6 weeks post-inoculation (Figure 1A). HA carrier-only
animals demonstrated no difference from controls confirming in vitro data that HA has no
direct anti-cancer activity. The intravenous standard CDDP-treated animals demonstrated a
tumor-growth delay of about 3 weeks compared with controls (p <0.05) with a median survival
of 12 weeks (compared to 7 weeks in controls p<0.01; Figure 1B). HA-Pt treated animals had
an initial delay in tumor growth of 5 weeks (p<0.01 compared to controls but this was NS
compared to i.v. CDDP with both curves meeting by 12 weeks post-inoculation) with a median
survival of 12 weeks as well. However there was one animal in the HA-Pt group who
demonstrated a true complete response to treatment with no measurable tumor and survival
well exceeding 24 weeks (upper limit of study). There were no complete responders in the
intravenous CDDP group.
Pathology
At the conclusion of the 30-day toxicity study, animals were euthanized and a full pathological
examination performed. Brain tissue and underlying tissue of the injection site were noted to
be normal in appearance with no microscopic changes for all study groups. Very mild changes
in lymph nodes were detected for high dose i.v. CDDP (3.3 mg/kg) and s.c. HA-Pt. Very mild
changes were observed in the livers for animals receiving both low dose CDDPi.v. (1.0 mg/
kg) and low dose HA-Pt s.c. indicated by the presence of mild inflammation in the sinusoids
(Figure 1C). Mild degeneration with some sinusoidal necroses were observed for animals
receiving high dose i.v. CDDP and high dose s.c. HA-Pt treatment. Necroses, however, were
more severe in the i.v.CDDP group. In addition, 60% of animals receiving low dose i.v.CDDP
were observed to develop mild renal necrosis including hemorrhage into the renal tubules along
with tubular edema. In contrast, none of the animals receiving low dose s.c. HA-Pthad renal
tubular necrosis. Similarly, 4 of 5 (80%) animals receiving high dose i.v. CDDP compared to
1 of 5 (20%) animals receiving high dose s.c. HA-Pt were diagnosed with mild renal tubular
necrosis. Overall, the pathology studies demonstrated that the HA-Pt conjugates had lower
incidence of both renal and hepatic toxicity compared to the conventional i.v.CDDP treatment
at all dose ranges. Additionally no neurotoxicity in the brain or local injection site toxicity in
the underlying muscle tissue was observed in the treated animals (data not shown).
DISCUSSION
Locally advanced breast cancer in women remains a challenge for treatment, with current
multimodality therapy resulting in moderate toxicity both locoregionally and systemically.
Locoregional relapse of breast cancer can occur in up to 13% of patients, and a complete axillary
lymphadenectomy can reduce this risk to less than 2%, but carries its own surgical risks and
morbidity including numbness in the upper medial arm, axilla and chest wall, increased
incidence of skin and wound infections, and painful lymphedema in up to 30–50% of
patients18–20. Cytotoxic chemotherapies also have poor penetration to the locoregional
lymphatics in the breast due to separation of the lymphatics from the systemic vasculature as
well as lymphatic mono-directional flow 21. Platinum-based chemotherapy is the most
commonly used chemotherapeutic in the United States, but carries its own morbidity including
dose-limiting nephrotoxicity and neurotoxicity. CDDP is not commonly used as a single-agent
treatment for breast cancer although it is a part of several combination regimens, but CDDP
may have a place in patient populations that have failed to respond to anthracyclines and
taxanes. Triple-negative breast cancers are commonly resistant to standard regimens, but
increasing evidence that these patients may have increased platinum sensitivity22. Recent
studies report that BRCA1 breast cancers are highly sensitive to platinums due to the role
BRCA1 plans in DNA double-strand repair 23–24.
Cohen et al. Page 4













Lymphatically delivered chemotherapy through a subcutaneous injection is a novel approach
to drug delivery that has only recently been shown by our group to be feasible with CDDP.
13 Nanoconjugation of CDDPto hyaluronic acid not only allows for improved locoregional
delivery of drug to the site of greatest tumor burden in the breast and axillary tissues, but also
decreases the level of renal toxicity associated with this drug. Our toxicity data demonstrate
that there is no significant injection site toxicity on pathologic analysis indicating that when
bound to the carrier, CDDP does not lead to necrosis of the surrounding tissue. It is only after
the carrier is cleaved from the conjugate by either hyaluronidase or receptor-mediated
endocytosis (hyaluronan is a ligand for CD44 receptors overexpressed on lymph nodes and
many cancers including breast cancers and melanoma) that the drug becomes functionally
active. In our formal tissue toxicology analysis, both renal and hepatic toxicity was significantly
reduced in the HA-Pt treated animals compared to the standard CDDP treated group.
The other benefit noted in the nanoconjugate group involved efficacy in tumor growth
inhibition and response in vivo. The HA-Pt vs. CDDP tumor-growth curves in Figure 1A
demonstrate that both drugs effectively delay tumor growth in an orthotopic, lymph-node
metastatic model of breast cancer. The HA-Pt group had an improved although not statistically
significant arrest in tumor growth (about 2–3 week additional delay compared to CDDP and
5–6 week delay compared to controls). What is significant is that a complete response was seen
in 20% of the HA-Pt-treated group and in 0% of the CDDP-treated group (Figure 1A–B). These
data support that HA-Pt injected subcutaneously in the breast has mildly improved efficacy
over standard CDDP injected intravenously. With improved efficacy and reduced toxicity with
the nanoconjugate formulation in a metastatic breast cancer model in vivo, these data provide
solid support for completing further preclinical proof of concept studies to advance this
formulation into clinical applications. The benefits of a locally injectable chemotherapeutic
over an intravenous infusion include potentially lower cost since the patient does not have to
be attached to an infusion pump with nursing or physician supervision as well as the ability to
deliver CDDP weekly with the sustained release properties of the nanoconjugate as opposed
to daily in most current intravenous protocols. The sustained-release properties of this
nanoconjugate provide an excellent boost to locoregional tumor tissues while maintaining
therapeutic systemic levels and provides promise for future potential use in LABC in both the
neoadjuvant or adjuvant setting. In addition, localized therapy may an effective addition to
systemic therapy in patients with metastatic disease; localized therapy can provide a higher
dose of chemotherapeutic in the most at risk tissues than is possible with systemic therapy
alone. Other published and ongoing studies have demonstrated that HA-Pt given locoregionally
provides adequate systemic levels of CDDP including serum AUC levels greater than
intravenous CDDP but without the high (toxic) peak serum concentrations of intravenous
therapy13. As a result, we hypothesize that these nanoconjugates would have a useful role in
the treatment of locally advanced breast cancer in the neoadjuvant setting, providing enhanced
locoregional drug efficacy while maintaining or even enhancing systemic therapy to distant
disease. Further studies will be necessary to evaluate long-term efficacy and toxicity in animal
models as well as the role of this nanoconjugate in combination chemotherapy regimens.
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(A) Measurement of tumor size. Animals were administered saline, HA, or equivalent doses
of CDDP and HA-Pt(3.3 mg/kg platinum basis). (B)Survival curves of animals treated by
CDDP or HA-Pt. Survival criteria were tumor volume less than 1000 mm3 and no tumor
ulceration or infection (n=5). (C)Kidneys of the s.c. HA-Pt group had a normal apperance
except for sparse minimal tubular cell necrosis; whereas, the i.v. CDDP treatment group had
pyknotic nuclei and apoptosis in the medullary tubular epithelia cells. Livers of the s.c. HA-
Pt group had very minor hepatitis but otherwise appeared normal; whereas, the i.v. CDDP
treatment group had necrotizing lesions and hepatitis. Sprague-Dawley rats were injected
subcutaneously into the mammary fat pad with HA-Pt or intravenously with CDDP (3.3 mg/
kg). Slides are typical of animals in each study group (n=5).
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